国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

重組蛋白

產品名稱 貨號 規格
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Ferrochelatase (hemH) CSB-YP873889CZA
CSB-EP873889CZA
CSB-BP873889CZA
CSB-MP873889CZA
CSB-EP873889CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 50S ribosomal protein L7/L12 (rplL) CSB-YP873890CZA
CSB-EP873890CZA
CSB-BP873890CZA
CSB-MP873890CZA
CSB-EP873890CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 50S ribosomal protein L33 (rpmG) CSB-YP873891CZA
CSB-EP873891CZA
CSB-BP873891CZA
CSB-MP873891CZA
CSB-EP873891CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Prolipoprotein diacylglyceryl transferase (lgt), partial CSB-YP873892CZA1
CSB-EP873892CZA1
CSB-BP873892CZA1
CSB-MP873892CZA1
CSB-EP873892CZA1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 6,7-dimethyl-8-ribityllumazine synthase (ribH) CSB-YP873893CZA
CSB-EP873893CZA
CSB-BP873893CZA
CSB-MP873893CZA
CSB-EP873893CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 UPF0323 lipoprotein Cj0371 (Cj0371) CSB-YP873894CZA
CSB-EP873894CZA
CSB-BP873894CZA
CSB-MP873894CZA
CSB-EP873894CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 3-oxoacyl-[acyl-carrier-protein] synthase 3 (fabH) CSB-YP873895CZA
CSB-EP873895CZA
CSB-BP873895CZA
CSB-MP873895CZA
CSB-EP873895CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Diaminopimelate decarboxylase (lysA) CSB-YP873896CZA
CSB-EP873896CZA
CSB-BP873896CZA
CSB-MP873896CZA
CSB-EP873896CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Aspartate 1-decarboxylase (panD) CSB-YP873897CZA
CSB-EP873897CZA
CSB-BP873897CZA
CSB-MP873897CZA
CSB-EP873897CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase (fabZ) CSB-YP873898CZA
CSB-EP873898CZA
CSB-BP873898CZA
CSB-MP873898CZA
CSB-EP873898CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 50S ribosomal protein L20 (rplT) CSB-YP873899CZA
CSB-EP873899CZA
CSB-BP873899CZA
CSB-MP873899CZA
CSB-EP873899CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Threonine--tRNA ligase (thrS), partial CSB-YP873900CZA
CSB-EP873900CZA
CSB-BP873900CZA
CSB-MP873900CZA
CSB-EP873900CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Molybdenum cofactor biosynthesis protein A (moaA) CSB-YP873901CZA
CSB-EP873901CZA
CSB-BP873901CZA
CSB-MP873901CZA
CSB-EP873901CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Probable rRNA maturation factor (Cj0121) CSB-YP873902CZA
CSB-EP873902CZA
CSB-BP873902CZA
CSB-MP873902CZA
CSB-EP873902CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Glutamate 5-kinase (proB) CSB-YP873903CZA
CSB-EP873903CZA
CSB-BP873903CZA
CSB-MP873903CZA
CSB-EP873903CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter jejuni subsp. jejuni serotype O:2 Dihydroxy-acid dehydratase (ilvD), partial CSB-YP873904CZA
CSB-EP873904CZA
CSB-BP873904CZA
CSB-MP873904CZA
CSB-EP873904CZA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chlamydia muridarum Protein MurJ homolog (murJ), partial CSB-YP873905CIU
CSB-EP873905CIU
CSB-BP873905CIU
CSB-MP873905CIU
CSB-EP873905CIU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chlamydia muridarum UvrABC system protein B (uvrB), partial CSB-YP873906CIU
CSB-EP873906CIU
CSB-BP873906CIU
CSB-MP873906CIU
CSB-EP873906CIU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chlamydia muridarum DNA mismatch repair protein mutL (mutL), partial CSB-YP873907CIU
CSB-EP873907CIU
CSB-BP873907CIU
CSB-MP873907CIU
CSB-EP873907CIU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chlamydia muridarum Aspartate--tRNA ligase (aspS), partial CSB-YP873908CIU
CSB-EP873908CIU
CSB-BP873908CIU
CSB-MP873908CIU
CSB-EP873908CIU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質形式,可以通過多種方式產生大量蛋白質、修改基因序列和制造有用的商業產品。重組蛋白的技術資源在重組蛋白的開發過程中,除了表達系統之外,還面臨著一系列令人困惑的選擇,如表達載體的選擇、表達蛋白的長度(全長或部分)、是否帶標簽等。在生產重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質量的重組蛋白,后續的實驗更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質量和純度不符合要求。在這里,來自CUSABIO的蛋白表達工程師根據他們開發重組蛋白的經驗總結出了幾個有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產,在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產重組蛋白。

第二條:如何選擇合適的表達載體?

表達載體是一種DNA分子,它攜帶特定的基因進入宿主細胞,并利用細胞的蛋白質合成機制來產生由該基因編碼的蛋白質。表達載體可使外源基因在宿主細胞中高效表達,經過多年的發展,表達載體已成為一種成熟而受歡迎的生物技術。在重組蛋白生產過程中是一種基本成分。正如標題所示,本文主要總結了幾個有用的技巧來選擇合適的表達載體。

第三條:如何表達具有生物活性的蛋白質?

根據重組蛋白的不同應用,對其生物活性有不同的要求。但是我們如何確保蛋白質的產生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.jhhuazhong.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達服務,您可以點擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質有任何疑問,涉及到蛋白質的價格、交貨、質量等,您可以點擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>